Page last updated: 2024-11-13

ampicillin sodium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID23663979
CHEMBL ID1200758
CHEBI ID34535
SCHEMBL ID40521
MeSH IDM0330775

Synonyms (110)

Synonym
austrapen
totacillin
ampiplus simplex
smr000059229
MLS000028726 ,
ampicillin sodium salt
ampicillin sodium
PRESTWICK_822
69-52-3
omnipen-n (tn)
ampicillin sodium (jp17/usp)
viccillin (tn)
D02119
ampicillin natrium
sodium ampicillin
sodium p-50
sodium (2s-(2alpha,5alpha,6beta(s*)))-6-(aminophenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
citteral
totacillin-n
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-, sodium salt, d-(-)-
domicillin
amcill-s
monosodium (2s,5r,6r)-6-((r)-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
binotal sodium
alpen-n
penbritin-s
pen a/n
einecs 200-708-1
d(-)-alpha-aminobenzylpenicillin sodium salt
monosodium d-(-)-6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, monosodium salt, (2s-(2alpha,5alpha,6beta(s*)))-
sodium d-(-)-alpha-aminobenzylpenicillin
sodium binotal
penialmen
omnipen-n
principen/n
SPECTRUM1500123
sodium, ampicillin
sodium (2s,5r,6r)-6-{[(2r)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
CHEBI:34535 ,
sodium 6beta-[(2r)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate
HMS2091I21
ampicillin (as sodium)
CHEMBL1200758
nsc-755864
ampicillinum natricum
ampicillin sodium, sterile
HMS501H08
HMS1920C21
A836527
sodium (2s,5r,6r)-6-((r)-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
HMS2232J12
S3170
AKOS015967315
CCG-39691
jfn36l5s8k ,
nsc 755864
unii-jfn36l5s8k
ampicillin sodium [usan:usp:jan]
ampicillin sodium, sterile [who-ip]
ampicillin sodium [usp-rs]
ampicillinum natricum [who-ip latin]
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, monosodium salt, (2s-(2.alpha.,5.alpha.,6.beta.(s*)))-
ampicillin sodium [orange book]
ampicillin sodium [usan]
ampicillin sodium [who-ip]
ampicillin sodium (non-injectable) [who-ip]
ampicillin sodium [mart.]
ampicillin sodium [vandf]
ampicillin sodium [ep monograph]
ampicillin sodium [green book]
ampicillin sodium [who-dd]
ampicillin sodium [usp monograph]
ampicillin sodium salt [mi]
ampicillin sodium [jan]
ampicillin (sodium)
HY-B0522A
A-7700
SCHEMBL40521
KLOHDWPABZXLGI-YWUHCJSESA-M
ampicillin sodium salt, antibiotic for culture media use only
AKOS025147373
OPERA_ID_709
mfcd00064313
ampicillin sodium salt, cell culture grade
sodium;(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
AC-8806
d-(-)-a-aminobenzylpenicillin sodium salt
SW220219-1
ampicillinsodiumsalt
DTXSID60988759
Q27116136
d-(-)-alpha-aminobenzylpenicillin &sdot
sodium(2s,5r,6r)-6-((r)-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
d-(-)--aminobenzylpenicillin sodium salt
BA166035
(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, sodium salt (1:1)
ampicillin sodium (mart.)
monosodium (2s,5r,6r)-6-((2r)-2-amino-2-phenylacetylamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
ampicillin sodium (non-injectable)
sodium 6beta-((2r)-2-amino-2-phenylacetamido)-2,2-dimethylpenam-3alpha-carboxylate
sodium (2s,5r,6r)-6-(((2r)-2-amino-2-phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
ampicillin sodium (ep monograph)
ampicillin sodium (usp monograph)
ampicillin sodium (usan:usp:jan)
ampicillin injection
amp-equine
d-(-)-6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, sodium salt
ampicillin sodium (usp-rs)
ampicilline sodium salt
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency28.18380.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency70.79460.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency28.62880.044717.8581100.0000AID485294; AID485341
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency12.55940.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency14.12540.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency25.11890.125919.1169125.8920AID2549
Chain A, CruzipainTrypanosoma cruziPotency25.11890.002014.677939.8107AID1476
chaperonin-containing TCP-1 beta subunit homologHomo sapiens (human)Potency22.38723.981127.764939.8107AID504842
USP1 protein, partialHomo sapiens (human)Potency28.18380.031637.5844354.8130AID743255
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency3.54810.707912.194339.8107AID720542
alpha-galactosidaseHomo sapiens (human)Potency50.11874.466818.391635.4813AID2107
Bloom syndrome protein isoform 1Homo sapiens (human)Potency31.62280.540617.639296.1227AID2528
DNA polymerase betaHomo sapiens (human)Potency12.58930.022421.010289.1251AID485314
DNA polymerase eta isoform 1Homo sapiens (human)Potency44.66840.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency39.81070.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency3.28560.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency50.11870.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (52)

Assay IDTitleYearJournalArticle
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1529820Antibacterial activity against Escherichia coli CGMCC 1.1636 after 12 to 14 hrs by double dilution method2018European journal of medicinal chemistry, Dec-05, Volume: 160Design, synthesis and biological evaluations of quaternization harman analogues as potential antibacterial agents.
AID645252Antibacterial activity against methicillin-resistant Staphylococcus aureus after 24 hrs by micro-broth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Three novel cyclic hexapeptides from Streptomyces alboflavus 313 and their antibacterial activity.
AID1529818Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 12 to 14 hrs by double dilution method2018European journal of medicinal chemistry, Dec-05, Volume: 160Design, synthesis and biological evaluations of quaternization harman analogues as potential antibacterial agents.
AID1268771Antibacterial activity against Ralstonia solanacearum after 12 to 16 hrs by plate reader analysis2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis, in vitro antibacterial activities of a series of 3-N-substituted canthin-6-ones.
AID1529826Thermal stability of the compound at 2 ug/ml at 65 degC after 6 hrs by UHPLC-ESI-MS/MS analysis2018European journal of medicinal chemistry, Dec-05, Volume: 160Design, synthesis and biological evaluations of quaternization harman analogues as potential antibacterial agents.
AID1529817Antibacterial activity against Staphylococcus aureus CGMCC 1.8721 after 12 to 14 hrs by double dilution method2018European journal of medicinal chemistry, Dec-05, Volume: 160Design, synthesis and biological evaluations of quaternization harman analogues as potential antibacterial agents.
AID706078Stimulation of Escherichia coli FtsZ self-polymerization at 40 ug/mL by microtiter plate-based light scattering assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.
AID645250Antibacterial activity against Staphylococcus aureus CGMCC 1.89 after 24 hrs by micro-broth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Three novel cyclic hexapeptides from Streptomyces alboflavus 313 and their antibacterial activity.
AID645249Antibacterial activity against Bacillus subtilis CGMCC 1.88 after 24 hrs by micro-broth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Three novel cyclic hexapeptides from Streptomyces alboflavus 313 and their antibacterial activity.
AID645251Antibacterial activity against Escherichia coli CGMCC 1.1574 after 24 hrs by micro-broth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Three novel cyclic hexapeptides from Streptomyces alboflavus 313 and their antibacterial activity.
AID645248Antibacterial activity against Bacillus cereus CGMCC 1.1846 after 24 hrs by micro-broth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Three novel cyclic hexapeptides from Streptomyces alboflavus 313 and their antibacterial activity.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1268770Antibacterial activity against Pseudomonas solanacearum after 12 to 16 hrs by plate reader analysis2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis, in vitro antibacterial activities of a series of 3-N-substituted canthin-6-ones.
AID645247Antibacterial activity against Pseudomonas aeruginosa CGMCC 1.2031 after 24 hrs by micro-broth dilution method2012European journal of medicinal chemistry, Apr, Volume: 50Three novel cyclic hexapeptides from Streptomyces alboflavus 313 and their antibacterial activity.
AID1529819Antibacterial activity against Bacillus cereus CGMCC 1.1846 after 12 to 14 hrs by double dilution method2018European journal of medicinal chemistry, Dec-05, Volume: 160Design, synthesis and biological evaluations of quaternization harman analogues as potential antibacterial agents.
AID471339Antibacterial activity against Staphylococcus aureus CMCC B26003 at 10 ug/disk after 24 hrs by paper disk method2009Journal of natural products, Sep, Volume: 72, Issue:9
Spirobisnaphthalene analogues from the endophytic fungus Preussia sp.
AID1529822Antibacterial activity against Ralstonia solanacearum CGMCC 1.12711 measured after 12 to 14 hrs by double dilution method2018European journal of medicinal chemistry, Dec-05, Volume: 160Design, synthesis and biological evaluations of quaternization harman analogues as potential antibacterial agents.
AID706053Antimicrobial activity against ESBL producing Escherichia coli ATCC BAA-201 expressing TEM3 lactamase incubated for 24 hrs by broth microdilution method2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1268768Antibacterial activity against Staphylococcus aureus after 12 to 16 hrs by plate reader analysis2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis, in vitro antibacterial activities of a series of 3-N-substituted canthin-6-ones.
AID1529821Antibacterial activity against Bacillus subtilis 769 after 12 to 14 hrs by double dilution method2018European journal of medicinal chemistry, Dec-05, Volume: 160Design, synthesis and biological evaluations of quaternization harman analogues as potential antibacterial agents.
AID1529825Thermal stability of the compound at 2 ug/ml at 37 degC after 6 hrs by UHPLC-ESI-MS/MS analysis2018European journal of medicinal chemistry, Dec-05, Volume: 160Design, synthesis and biological evaluations of quaternization harman analogues as potential antibacterial agents.
AID706051Antimicrobial activity against Escherichia coli N43 expressing AcrAB efflux pump mutant incubated for 24 hrs by broth microdilution method2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1268769Antibacterial activity against Bacillus cereus after 12 to 16 hrs by plate reader analysis2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis, in vitro antibacterial activities of a series of 3-N-substituted canthin-6-ones.
AID706052Antimicrobial activity against Escherichia coli W4573 incubated for 24 hrs by broth microdilution method2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (12.50)29.6817
2010's13 (81.25)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.37 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index68.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]